Structure-activity relationships of benzothiazole GPR35 antagonists

Real samples sensitive dopamine sensor based on poly 1,3-benzothiazol-2-yl((4-carboxlicphenyl)hydrazono)acetonitrile on a glassy carbon electrode

Herein, a novel electrochemical sensor that was used for the first time for sensitive and selective detection of dopamine (DA) was fabricated. The new sensor is based on the decoration of the glassy carbon electrode surface (GC) with a polymer film of 1,3-Benzothiazol-2-yl((4-carboxlicphenyl)hydrazono)) acetonitrile (poly(BTCA). The prepared (poly(BTCA) was examined by using different techniques such as 1H NMR, 13C NMR, FTIR, and UV-visible spectroscopy. The electrochemical investigations of DA were assessed using cyclic voltammetry (CV) and differential pulse voltammetry (DPV). The results obtained showed that the modifier increased the electrocatalytic efficiency with a noticeable increase in the oxidation peak current of DA in 0.1 M phosphate buffer solution (PBS) at an optimum pH of 7.0 and scan rate of 200 mV/s when compared to unmodified GC. The new sensor displays a good performance for detecting DA with a limit of detection (LOD 3σ), and limit of quantification (LOQ 10σ) are 0.28 nM and 94 nM respectively. The peak current of DA is linearly proportional to the concentration in the range from 0.1 to 10.0 µM. Additionally, the fabricated electrode showed sufficient reproducibility, stability, and selectivity for DA detection in the presence of different interferents. The proposed poly(BTCA)/GCE sensor was effectively applied to detect DA in the biological samples.

Cannabinoids Modulate Neuronal Activity and Cancer by CB1 and CB2 Receptor-Independent Mechanisms

Cannabinoids include the active constituents of Cannabis or are molecules that mimic the structure and/or function of these Cannabis-derived molecules. Cannabinoids produce many of their cellular and organ system effects by interacting with the well-characterized CB1 and CB2 receptors. However, it has become clear that not all effects of cannabinoid drugs are attributable to their interaction with CB1 and CB2 receptors. Evidence now demonstrates that cannabinoid agents produce effects by modulating activity of the entire array of cellular macromolecules targeted by other drug classes, including: other receptor types; ion channels; transporters; enzymes, and protein- and non-protein cellular structures. This review summarizes evidence for these interactions in the CNS and in cancer, and is organized according to the cellular targets involved. The CNS represents a well-studied area and cancer is emerging in terms of understanding mechanisms by which cannabinoids modulate their activity. Considering the CNS and cancer together allow identification of non-cannabinoid receptor targets that are shared and divergent in both systems. This comparative approach allows the identified targets to be compared and contrasted, suggesting potential new areas of investigation. It also provides insight into the diverse sources of efficacy employed by this interesting class of drugs. Obtaining a comprehensive understanding of the diverse mechanisms of cannabinoid action may lead to the design and development of therapeutic agents with greater efficacy and specificity for their cellular targets.